Drug Review: Maribavir

PTB Reports, 2024, 10, 1, 17-18.
DOI: 10.5530/PTB.2024.10.3
Published: September 2024
Type: Drug Review
Authors: Juman Alsaab

 

Author(s) affiliations:

Juman Alsaab, Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract

Regulations: had been registered in the following countries: United States of America (U.S.A.). Registration number (S.A.): Not available. Insurance Drug Formulary (S.A.): Not available. General Information: Registered Company: Takeda Pharmaceuticals U.S.A., Inc. Regulatory Status: R.X. Mechanism of Action: Maribavir stands out with its unique protein kinase competitive inhibition of human CMV enzyme pUL97.